公开(公告)号：WO2007050784A2

公开(公告)日：2007-05-03

申请号：PCT/US2006/041832

申请日：2006-10-25

Applicant: CELATOR PHARMACEUTICALS, INC. ,  BATIST, Gerald ,  MAYER, Lawrence ,  SWENSON, Christine ,  JANOFF, Andrew ,  GELMON, Karen

Inventor： BATIST, Gerald ,  MAYER, Lawrence ,  SWENSON, Christine ,  JANOFF, Andrew ,  GELMON, Karen

IPC: A61K31/4745 ,  A61K31/505 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61K31/505

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.

Abstract translation: 本文提供了通过施用包含固定的，非拮抗摩尔比的伊立替康和氟尿苷的药物组合物来治疗癌症的方法。 这些方法特别可用于治疗晚期实体瘤的癌症患者。

公开(公告)号：WO2016140952A1

公开(公告)日：2016-09-09

申请号：PCT/US2016/020228

申请日：2016-03-01

Applicant: TAANEH, INC. ,  JANOFF, Andrew, S.

Inventor： JANOFF, Andrew, S.

IPC: G06K19/06

CPC classification number: A61K9/0019 ,  A61K9/0014 ,  A61K9/0043 ,  A61K9/006 ,  A61K9/0095 ,  A61K9/10 ,  A61K9/2009 ,  A61K9/2813 ,  A61K47/02

Abstract: Authentication systems for products employing populations containing particles of diamonds that have fluorescent emissions of various wavelengths, intensities and durations are described. By varying the populations of diamond particles in products to be labeled, multiple different identification systems can be obtained permitting authentication taggants for large numbers of different products. The use of diamond microparticles (diamond powder) for authenticating, identifying and constructing anti-counterfeiting systems pharmaceuticals, including but not limited to solid oral dosage forms, liquids, syrups, creams, and powders; as well as prestige cosmetics and fragrances, high-end wines and spirits (liquor), foods, textiles, paints, inks, currency, stamps (e.g., tax stamps), mechanical parts and packaging is described.

Abstract translation: 描述了使用含有具有各种波长，强度和持续时间的荧光发射的钻石颗粒的产品的认证系统。 通过改变要标记的产品中的金刚石颗粒的数量，可以获得许多不同的识别系统，允许许多不同产品的认证标签。 使用金刚石微粒（金刚石粉）来认证，鉴定和构建防伪系统药物，包括但不限于固体口服剂型，液体，糖浆，霜剂和粉剂; 以及声望化妆品和香水，高端葡萄酒和烈酒（酒），食品，纺织品，油漆，油墨，货币，邮票（例如税印），机械零件和包装。

公开(公告)号：WO2008101214A2

公开(公告)日：2008-08-21

申请号：PCT/US2008054168

申请日：2008-02-15

Applicant: CELATOR PHARMACEUTICALS INC ,  LOUIE ARTHUR ,  SWENSON CHRISTINE ,  MAYER LAWRENCE ,  JANOFF ANDREW

Inventor： LOUIE ARTHUR ,  SWENSON CHRISTINE ,  MAYER LAWRENCE ,  JANOFF ANDREW

IPC: A61K31/70 ,  A61K9/127 ,  A61P35/00

CPC classification number: A61K31/70 ,  A61K9/0019 ,  A61K9/127 ,  Y10T436/143333

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

Abstract translation: 本文提供了通过施用包含固定的非拮抗摩尔比的阿糖胞苷和蒽环霉素的药物组合物来治疗癌症的方法。 这些方法在治疗晚期血液癌症或增殖性疾病的患者中特别有用。

公开(公告)号：WO0051565A9

公开(公告)日：2002-02-14

申请号：PCT/US0005395

申请日：2000-03-01

Applicant: LIPOSOME CO INC ,  MEERS PAUL ,  SHANGGUAN TONG ,  CABRAL LILLY DONNA ,  JANOFF ANDREW ,  AHL PATRICK

Inventor： MEERS PAUL ,  SHANGGUAN TONG ,  CABRAL-LILLY DONNA ,  JANOFF ANDREW ,  AHL PATRICK

IPC: A61K9/127 ,  A61K9/133

CPC classification number: A61K9/1272 ,  A61K9/127

Abstract: This invention provides a method to prepare liposome-encapsulated bioactive agents such as nucleic acids, comprising complexation of the bioactive agents in reverse micelles prior to forming liposomes, as well as methods of using the liposomes so formed and formulations to deliver nucleic acids to cells.

Abstract translation: 本发明提供了一种制备脂质体包封的生物活性剂如核酸的方法，其包括在形成脂质体之前的反胶束中生物活性剂的复合，以及使用如此形成的脂质体和制剂将核酸递送至细胞的方法。

公开(公告)号：WO2008101214A3

公开(公告)日：2008-08-21

申请号：PCT/US2008/054168

申请日：2008-02-15

Applicant: CELATOR PHARMACEUTICALS, INC. ,  LOUIE, Arthur ,  SWENSON, Christine ,  MAYER, Lawrence ,  JANOFF, Andrew

Inventor： LOUIE, Arthur ,  SWENSON, Christine ,  MAYER, Lawrence ,  JANOFF, Andrew

IPC: A01N43/04 ,  A61K31/70

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

公开(公告)号：WO2007050784A3

公开(公告)日：2007-06-14

申请号：PCT/US2006041832

申请日：2006-10-25

Applicant: CELATOR PHARMACEUTICALS INC ,  BATIST GERALD ,  MAYER LAWRENCE ,  SWENSON CHRISTINE ,  JANOFF ANDREW ,  GELMON KAREN

Inventor： BATIST GERALD ,  MAYER LAWRENCE ,  SWENSON CHRISTINE ,  JANOFF ANDREW ,  GELMON KAREN

IPC: A61K31/4745 ,  A61K31/505 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61K31/505

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.

Abstract translation: 本文提供了通过施用包含固定的非拮抗摩尔比的伊立替康和氟尿苷的药物组合物治疗癌症的方法。 这种方法在治疗晚期实体瘤的癌症患者中特别有用。

公开(公告)号：WO2004090537A3

公开(公告)日：2004-10-21

申请号：PCT/US2004/010388

申请日：2004-04-02

Applicant: CELATOR TECHNOLOGIES INC. ,  JANOFF, Andrew, S. ,  MAYER, Lawrence ,  BALLY, Marcel

Inventor： JANOFF, Andrew, S. ,  MAYER, Lawrence ,  BALLY, Marcel

IPC: G01N33/50

Abstract: Compositions which comprise delivery vehicles having stably associated therewith predetermined, patient-specific combinations of two or more agents, such as antineoplastic agents, are useful in achieving optimal therapeutic effects on a patient-by-patient basis when combinations of drugs are administered.

公开(公告)号：WO2004090537A2

公开(公告)日：2004-10-21

申请号：PCT/US2004010388

申请日：2004-04-02

Applicant: CELATOR TECHNOLOGIES INC ,  JANOFF ANDREW S ,  MAYER LAWRENCE ,  BALLY MARCEL

Inventor： JANOFF ANDREW S ,  MAYER LAWRENCE ,  BALLY MARCEL

IPC: G01N33/50

CPC classification number: G01N33/5011 ,  C12N2503/02 ,  G01N33/5008 ,  G01N33/5014

Abstract: Compositions which comprise delivery vehicles having stably associated therewith predetermined, patient-specific combinations of two or more agents, such as antineoplastic agents, are useful in achieving optimal therapeutic effects on a patient-by-patient basis when combinations of drugs are administered.

Abstract translation: 包含递送载体的组合物与两种或更多种试剂（例如抗肿瘤剂）的预定的，患者特异性的组合相结合，在给予药物组合时可用于逐个患者实现最佳治疗效果。

公开(公告)号：WO1998014170A1

公开(公告)日：1998-04-09

申请号：PCT/US1997017513

申请日：1997-09-30

Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  THE LIPOSOME COMPANY, INC. ,  AGUS, David, B. ,  JANOFF, Andrew, S. ,  ZELENETZ, Andrew, D. ,  AHMAD, Imran ,  MAYHEW, Eric

Inventor： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  THE LIPOSOME COMPANY, INC.

IPC: A61K09/127

CPC classification number: A61K39/0011 ,  A61K9/1271 ,  A61K9/1272

Abstract: A patient-specific vaccine for non-Hodgkin's lymphoma and other B Cell disorders is made from a lipid-based carrier; and a tumor idiotype derived from B cells from the patient bound to the surface of the lip-based carrier. The idiotype may be absorbed directly to the surface of the lipid-based carrier or bound via an idiotype-binding moiety which is bound to the surface of the lipid-based carrier. When an idiotype binding moiety is used, this moiety is preferably protein G or protein A or a combination thereof. The idiotype need not be prepared from a hybridoma and the use of anti-idiotype murine-derived antibodies is not necessary. Instead, the idiotype can be captured directly from a tumor lysate or other patient-derived material. This makes it possible to prepare a composition in the accordance with the invention and to use it to start the development of an immune response within a period of hours or days, rather than a period of months. The lipid-based carrier is preferably a liposome and may be composed of such lipids as to be an effective adjuvant for the tumor vaccine. The immunotherapeutic composition of the invention can also include additional adjuvants or immunotherapeutic agents incorporated within the liposome. For example, the lipid-based carrier may contain granulocyte-macrophage colony stimulating factor (gmCSF) or cytokines such as interleukin-12 (IL-12) which enhance vaccine-induced immune response.

Abstract translation: 用于非霍奇金淋巴瘤和其他B细胞疾病的患者特异性疫苗由基于脂质的载体制成; 和衍生自结合到基于唇缘的载体表面的患者的B细胞的肿瘤独特型。 独特型可以直接吸收到基于脂质的载体的表面，或者通过与脂质载体的表面结合的独特型结合部分结合。 当使用独特型结合部分时，该部分优选蛋白G或蛋白A或其组合。 独特型不需要从杂交瘤制备，并且不需要使用抗独特型鼠源抗体。 相反，独特型可以直接从肿瘤裂解物或其他患者来源的材料中捕获。 这使得可以根据本发明制备组合物，并且可以在数小时或数天而不是几个月的时间内使用它来开始免疫应答的发展。 脂质载体优选为脂质体，并且可以由这样的脂质组成，作为肿瘤疫苗的有效佐剂。 本发明的免疫治疗组合物还可以包括掺入脂质体内的另外的佐剂或免疫治疗剂。 例如，基于脂质的载体可以含有粒细胞 - 巨噬细胞集落刺激因子（gmCSF）或细胞因子，例如增强疫苗诱导的免疫应答的白细胞介素-12（IL-12）。